ReviewAntimicrobial agents and chemotherapy2021
The Future of Antifungal Drug Therapy: Novel Compounds and Targets.
Review in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 123 citations in OpenAlex.
- Trial
- Covalent Inhibitors in Antimicrobial Drug Development-Beyond β-Lactams.Molecules (Basel, Switzerland) · 2026Review
- Antifungal Efficacy againstACS omega · 2026Article
- Significant Activity of Pytren-2Q, a 2‑Quinoline Polyamine Compound, against High-Concern Human Pathogenic Fungi.ACS omega · 2026Article
- Essential oil-based hydrogels for oral candidiasis: preliminary formulation development, antifungal efficacy, and computational analysis via Monte Carlo simulation.Frontiers in cellular and infection microbiology · 2026Article
- Recent Developments on Coumarin Hybrids as Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2025Review
- The sulfur-related metabolic status ofVirulence · 2025Article
- Epidemiology of Fungal Bloodstream Infections and Antifungal Susceptibility in a Tertiary Care Hospital in Riyadh, Saudi Arabia: A RarePathogens (Basel, Switzerland) · 2025Article
- Antifungal resistance: Emerging mechanisms and implications (Review).Molecular medicine reports · 2025Review
- An integrated systems biology approach establishes arginine biosynthesis as a metabolic weakness in Candida albicans during host infection.Cell communication and signaling : CCS · 2025Article
- Synergistic effect of synthetic derivatives of 1,3,4-thiadiazole with amphotericin B in antifungal therapy.Scientific reports · 2025Article
- Antifungal Structure-Activity Relationship Studies of Broad-Spectrum Phenothiazines.ACS omega · 2025Article
- The Significance of Fungal Specialized Metabolites in One Health Perspectives.International journal of molecular sciences · 2025Review
- HybridPharmaceuticals (Basel, Switzerland) · 2025Article
- Antimicrobial and antiparasitic potential of lupeol: antifungal effect on theJournal of medical microbiology · 2025Article
- Article
- Editorial: Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies.Frontiers in cellular and infection microbiology · 2025Article
- Discovery of novel targets for important human and plant fungal pathogens via an automated computational pipeline HitList.PloS one · 2025Article
- Article
- Exploring the Arsenal of Novel Antifungal Drug Targets for Combating Fungal Infections.Current pharmaceutical biotechnology · 2025Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Fungal infections are a universal problem and are routinely associated with high morbidity and mortality rates in immunocompromised patients. Existing therapies comprise five different classes of antifungal agents, four of which target the synthesis of ergosterol and cell wall glucans. However, the currently available antifungals have many limitations, including poor oral bioavailability, narrow therapeutic indices, and emerging drug resistance resulting from their use, thus making it essential to investigate the development of novel drugs which can overcome these limitations and add to the antifungal armamentarium. Advances have been made in antifungal drug discovery research and development over the past few years as evidenced by the presence of several new compounds currently in various stages of development. In the following minireview, we provide a comprehensive summary of compounds aimed at one or more novel molecular targets. We also briefly describe potential pathways relevant for fungal pathogenesis that can be considered for drug development in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.